Summary & Overview

Acute Leukemia with MCC: Inpatient Reimbursement Overview

DRG 834 addresses inpatient admissions for acute leukemia with a Major Complication or Comorbidity, representing high-acuity cases requiring significant resources. Proper classification matters because Diagnosis-Related Group assignment drives Medicare inpatient reimbursement and reflects the intensity of services and costs for these complex oncology patients.

Acute Leukemia with Major Complication or ComorbidityDRG Acute Leukemia with MCCDRG 834Diagnosis-Related GroupInpatient ReimbursementMedicareHematologyOncologyIntensive CareChemotherapy

DRG 834 Overview

DRG 834 covers inpatient stays for patients admitted with acute leukemia accompanied by a Major Complication or Comorbidity, reflecting high clinical complexity such as severe infections, organ dysfunction, or treatment-related toxicities. This classification captures cases that require intensive resource use, extended hospitalization, and specialized oncology and hematology care. For Medicare payment, assignment to this Diagnosis-Related Group influences higher reimbursement to account for the increased cost of care associated with severe complications. Accurate coding of diagnoses and complications is essential to ensure appropriate Medicare Severity Diagnosis-Related Group assignment and payment.

Clinical Trials

Early-phase acute intervention trials evaluating novel induction regimens or rapid cytoreductive strategies for patients admitted with newly diagnosed or relapsed acute leukemia complicated by life‑threatening cytopenias or leukostasis. These studies enroll hospitalized adults and pediatrics who need immediate disease control and assess endpoints such as time to remission, early mortality, transfusion needs, and recovery of marrow function; they are relevant to inpatient care teams and payers because effective rapid interventions can shorten ICU stays, reduce transfusion and supportive care utilization, and influence short‑term reimbursement and resource allocation.
Comparative effectiveness studies conducted during the inpatient episode that compare different supportive care protocols (for example, antimicrobial prophylaxis versus preemptive strategies, transfusion thresholds, or growth factor use) in patients with acute leukemia and major complications. These pragmatic trials typically enroll patients hospitalized for chemotherapy complications or febrile neutropenia and measure outcomes such as infection rates, length of stay, readmission, and total cost of care; results directly inform hospital protocols, utilization management, and payer coverage decisions aimed at optimizing outcomes while controlling inpatient resource use.
Post‑discharge outcomes and health services research following hospitalization for acute leukemia with major complications, focusing on readmission risk prediction, post‑discharge mortality, functional recovery, and long‑term costs. Cohort and registry studies follow patients after an acute inpatient episode to identify predictors of early readmission, durable remission, rehabilitation needs, and outpatient supportive care utilization; this research is important to providers and payers for designing care transition programs, targeted outpatient monitoring, and value‑based payment models to reduce avoidable readmissions and downstream expenditures.

Related Codes

836-ACUTE-LEUKEMIA-WITHOUT-CC-MCC

Acute Leukemia without CC/MCC: Inpatient Reimbursement Overview

823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

850-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES

Acute Leukemia with Other Procedures: Inpatient Reimbursement Overview

848-CHEMOTHERAPY-WITHOUT-ACUTE-LEUKEMIA-AS-SECONDARY-DIAGNOSIS-WITHOUT-CC-MCC

Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC: Inpatient Reimbursement Overview

837-CHEMOTHERAPY-WITH-ACUTE-LEUKEMIA-AS-SECONDARY-DIAGNOSIS-OR-WITH-HIGH-DOSE-CHEMOTHERAPY-AGENT-WITH-MCC

Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC: Inpatient Reimbursement Overview

845-OTHER-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASTIC-DIAGNOSES-WITHOUT-CC-MCC

Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses: Inpatient Reimbursement Overview

843-OTHER-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASTIC-DIAGNOSES-WITH-MCC

Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC: Inpatient Reimbursement Overview

821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

849-RADIOTHERAPY

Radiotherapy: Inpatient Reimbursement Overview

Showing 1–10 of 27

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.